BridgeBio Pharma, Inc. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
BridgeBio Pharma, Inc. (BBIO) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 58.34 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-08-10
- BridgeBio Pharma, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-03-31 was 59.79M shares, a 0.20% decline year-over-year.
- BridgeBio Pharma, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-03-31 was 59.92M shares, a 18.35% increase year-over-year.
- BridgeBio Pharma, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2024-03-31 was 50.63M shares, a 8.16% decline year-over-year.
- BridgeBio Pharma, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2023-03-31 was 55.13M shares, a 16.17% decline year-over-year.
- BridgeBio Pharma, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2025 was 54.00M shares, a 16.35% increase from fiscal 2024.
- BridgeBio Pharma, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2024 was 46.41M shares, a 1.80% decline from fiscal 2023.
- BridgeBio Pharma, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2023 was 47.26M shares, a 16.21% decline from fiscal 2022.
- BridgeBio Pharma, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2022 was 56.41M shares, a 7.95% increase from fiscal 2021.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | 58.34M shares 10-Q · filed 2026-08-10 | ||||
| 2026-03-31 | 59.79M shares 10-Q · filed 2026-05-07 | ||||
| 2025-12-31 | 54.00M shares 10-K · filed 2026-02-24 | ||||
| 2025-09-30 | 56.67M shares 10-Q · filed 2025-10-29 | ||||
| 2025-06-30 | 58.54M shares 10-Q · filed 2026-08-10 | ||||
| 2025-03-31 | 59.92M shares 10-Q · filed 2026-05-07 | ||||
| 2024-12-31 | 46.41M shares 10-K · filed 2026-02-24 | ||||
| 2024-09-30 | 46.49M shares 10-Q · filed 2025-10-29 | ||||
| 2024-06-30 | 48.11M shares 10-Q · filed 2025-08-05 | ||||
| 2024-03-31 | 50.63M shares 10-Q · filed 2025-04-29 | ||||
| 2023-12-31 | 47.26M shares 10-K · filed 2026-02-24 | ||||
| 2023-09-30 | 49.00M shares 10-Q · filed 2024-11-12 | ||||
| 2023-06-30 | 55.62M shares 10-Q · filed 2024-08-01 | ||||
| 2023-03-31 | 55.13M shares 10-Q · filed 2024-05-02 | ||||
| 2022-12-31 | 56.41M shares 10-K · filed 2025-02-20 | 52.25M shares 10-K · filed 2023-02-23 | |||
| 2022-09-30 | 55.79M shares 10-Q · filed 2023-11-02 | ||||
| 2022-06-30 | 70.11M shares 10-Q · filed 2023-08-03 | ||||
| 2022-03-31 | 65.76M shares 10-Q · filed 2023-05-04 | ||||
| 2021-12-31 | 52.25M shares 10-K · filed 2024-02-22 | ||||
| 2021-09-30 | 39.22M shares 10-Q · filed 2022-11-03 | ||||
| 2021-06-30 | 38.90M shares 10-Q · filed 2022-08-04 | ||||
| 2021-03-31 | 39.39M shares 10-Q · filed 2022-05-05 | ||||
| 2020-12-31 | 29.24M shares 10-K · filed 2023-02-23 | ||||
| 2020-09-30 | 26.18M shares 10-Q · filed 2021-11-04 | ||||
| 2020-06-30 | 26.52M shares 10-Q · filed 2021-08-05 | ||||
| 2020-03-31 | 23.13M shares 10-Q · filed 2021-05-06 | ||||
| 2019-12-31 | 10.72M shares 10-K · filed 2022-02-25 | ||||
| 2019-09-30 | 10.02M shares 10-Q · filed 2020-11-05 | ||||
| 2019-06-30 | 10.56M shares 10-Q · filed 2020-08-11 | ||||
| 2019-03-31 | 7.42M shares 10-Q · filed 2020-05-14 | ||||
| 2018-12-31 | 5.36M shares 10-K · filed 2021-02-25 | ||||
| 2018-09-30 | 5.33M shares 10-Q · filed 2019-11-08 | ||||
| 2017-12-31 | 6.63M shares 10-K · filed 2020-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |